Cyclooctanamine

Cyclooctanamine

SCHEMBL6810973

NC1CCCCCCC1.NC1CCCc2ccccc21

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.50
EPHX1 P07099 1/20 0.43
PRCP P42785 1/20 0.42
SIGMAR1 Q99720 2/20 0.42
PLAU P00749 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10789533 0.91 IDO1 (0.50) IDO1EPHX1PRCPSIGMAR1
SCHEMBL14543304 0.91 IDO1 (0.58) IDO1
SCHEMBL469047 0.91 IDO1 (0.58) IDO1
SCHEMBL29415502 0.91 IDO1 (0.58) IDO1
SCHEMBL30837489 0.91 IDO1 (0.58) IDO1
SCHEMBL40422 0.91 IDO1 (0.58) IDO1
SCHEMBL10774751 0.91 IDO1 (0.58) IDO1
SCHEMBL44600 0.91 IDO1 (0.58) IDO1
Hydrochloric Acid SCHEMBL1874441 0.89 IDO1 (0.59) IDO1
Bromide SCHEMBL3727459 0.89 IDO1 (0.56) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT IDO1 78/4885EPHX1 1124/4885PRCP 1783/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI IDO1 94/4885EPHX1 982/4885PRCP 1740/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI IDO1 94/4885EPHX1 982/4885PRCP 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.